Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
02 August 2021 | Story Leonie Bolleurs | Photo Supplied
Prof Maryke Labuschagne, a successful scientist who is doing great work to enhance food security on the African continent, admires women who have made an impact, often in male-dominated environments.

Maryke Labuschagne, Professor in Plant Breeding at the University of the Free State (UFS), is known to many for her work to enhance food security. 

She holds the National Research Foundation’s South African Research Chairs Initiative (SARChI) Chair on Disease Resistance and Quality in Field Crops, travelling all over Africa to do research on the genetic improvement of staple food crops in communities. Through decades of research and collaboration, she has also contributed to the establishment of a strong network of researchers on the continent.

During an interview in celebration of Women’s Month, Prof Labuschagne talks about her experiences as a young scientist and how she believes young female researchers should be supported and nurtured. 

Is there a woman who inspires you and who you would like to celebrate this Women’s Month, and why?

Besides the scientists she had the opportunity to work with in countries such as Zimbabwe, Zambia, Uganda, Ghana, Ethiopia, Kenya, Lesotho, Eswatini, Tunisia, and Ethiopia, she also met women who are working the fields to produce crops for their families, raising their children, and living in difficult conditions. “These women, who make it work against all odds, inspire me,” says Prof Labuschagne.

Other women she admires and who have made an impact – often in male-dominated environments – include role models from the past, such as former UK prime minister, Margaret Thatcher; physicist Marie Curie, who was far ahead of her time; and American geneticist Barbara McClintock, who won a Nobel Prize in 1983. 

What is your response to current challenges faced by women and available platforms for women development?
 
“When I started working in the Faculty of Natural and Agricultural Sciences at the UFS in 1989, it was a different world. It was a totally (white) male-dominated environment. The number of women scientists could be counted on the fingers of one hand, and they were often not given the same opportunities as their male counterparts,” she recalls.

Prof Labuschagne continues: “With women having so many opportunities today, it is now totally different.”

She believes women will always have a double burden – being responsible for a family and having to compete on an equal footing with male colleagues in the workplace. There are now, however, many platforms and support systems specifically for women, and she encourages women to make use of every available form of assistance they can get.

I would say you can have it all. Work hard, believe in yourself, follow your dreams, focus on your goals, see the opportunities – not the challenges, and leave a legacy. – Prof Maryke Labuschagne
 
What advice would you give to the 15-year-old you?

“I would say you can have it all. Work hard, believe in yourself, follow your dreams, focus on your goals, see the opportunities – not the challenges, and leave a legacy.”

She is convinced that young women can have a family and a career, even if they believe it is not possible. 
 
What would you say makes women of quality, impact, and care?
 
“I see many women at the UFS making their mark, making an impact in their chosen fields.”

According to Prof Labuschagne, what would have been unthinkable just a few decades ago, such as women serving as deans and in top management positions, is now a reality. 

“I see young female researchers boldly taking on the world, believing in themselves and their abilities, and knowing they will be successful.” She states that each of these women should be supported and nurtured, as they will have a huge influence on the course of the university’s future.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept